AbbVievs.Pfizer
ABBV vs PFE · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
AbbVie is about 3.0× larger than Pfizer by market cap; Pfizer trades at the lower P/E (36.3 vs 76.0); year to date, AbbVie leads (+18.8% vs +12.4%).
Side by side
| ABBV | PFE | |
|---|---|---|
| Market cap | $480B | $157B |
| Price | $272.42 | $27.82 |
| Today | +0.4% | −0.6% |
| Return YTD | +18.8% | +12.4% |
| Return 1Y | +16.5% | +6.6% |
| Since June 26, 2026 | +7.5% | +14.5% |
| P/E | 76.0 | 36.3 |
| P/S | 7.4 | 2.5 |
| P/B | 337.7 | 1.8 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
AbbVieABBV
Skyrizi and Rinvoq carry the immunology franchise. Oncology and neuroscience follow, plus the aesthetics business built around Botox.
Full ABBV profile →PfizerPFE
Vaccines are what most people associate with Pfizer. The portfolio is considerably broader: oncology is a large part of it, and internal medicine covers much of the rest.
Full PFE profile →More ABBV & PFE comparisons
Other head-to-heads in the Big pharma segment.